Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

EGFR targeting of solid tumors.

Caio M Rocha-Lima1, Heloisa P Soares, Luis E Raez

  • 1Department of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, FL 33136, USA. crochalima@miami.edu

Cancer Control : Journal of the Moffitt Cancer Center
|July 7, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC).

International journal of molecular sciences·2026
Same author

Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial.

JAMA·2026
Same author

The Equivalents Are Coming! Developing a Shared Nomenclature for Radiopharmaceutical Therapy of Neuroendocrine Tumors, Prostate Cancer, and Beyond.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Assessing Patient Characteristics in Neuroendocrine Tumor Research: A Comparison of the NET-PRO Study to SEER Population-Based Data.

Endocrine·2026
Same author

Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315).

The oncologist·2026
Same author

Ready, Set, Screen: Evaluating Community Readiness for Lung Cancer Screening Among Non-Hispanic Black Populations in Florida: Brief Report.

JTO clinical and research reports·2026

Epidermal growth factor receptor (EGFR)-targeted therapies show promise for various cancers. Ongoing research explores new applications and combinations, with patient selection being key for successful treatment.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR)-targeted agents show potential in cancer treatment.
  • Recent clinical trials indicate benefits for numerous cancer patients.

Purpose of the Study:

  • Review the current status of EGFR-targeted therapies in cancer.
  • Address the efficacy of these drugs as monotherapy or in combination treatments.

Main Methods:

  • Literature review of EGFR-targeted therapies.
  • Analysis of clinical trial data for efficacy and approved indications.

Main Results:

  • Cetuximab and panitumumab are FDA-approved for metastatic colorectal cancer.
  • Erlotinib is approved for advanced/metastatic lung and pancreatic cancers (in combination).

Related Experiment Videos

  • Multiple EGFR tyrosine kinase inhibitors and monoclonal antibodies are under investigation for various cancers.

    • Conclusions:

    • EGFR-targeted agents are effective in specific cancer scenarios.
    • Further research is exploring new cancer types and combination treatments.
    • Patient selection based on biomarkers will enhance treatment success.